Bionomics Limited announced the top line results of the exploratory trial of BNC210 for the treatment of agitation in elderly patients in a hospital setting. The results of the Agitation trial indicated that BNC210 treatment did not differentiate from placebo on the primary and secondary efficacy end points. Comparison of mean peak daily Pittsburgh Agitation Scale scores (observations of aberrant vocalisation, motor agitation, aggressiveness and resisting care) showed a gradual improvement for both BNC210 and placebo over the 5-day treatment period, but without evidence of a treatment effect. This exploratory Phase 2 study was designed to assess the therapeutic potential of BNC210 to treat agitation in hospitalised elderly patients as a separate indication and to evaluate safety of BNC210 in the elderly patient population. The safety of BNC210 was confirmed. In continuing to build the case for BNC210, following feedback from potential partners and investors, Bionomics will invest in a single ascending dose study in healthy volunteers to demonstrate that blood levels of BNC210 believed to be necessary to meet the primary endpoints for effectiveness in treating PTSD in any further trial, are achievable using the new solid dose formulation. The cost of this study is estimated at $300,000 and results are anticipated to be available by early calendar year fourth quarter of 2019.